Virginia Retirement Systems ET AL reduced its position in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 70.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,000 shares of the biotechnology company’s stock after selling 36,300 shares during the quarter. Virginia Retirement Systems ET AL owned 0.07% of Concert Pharmaceuticals worth $209,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CNCE. Quantbot Technologies LP bought a new stake in Concert Pharmaceuticals during the first quarter worth $138,000. Hillsdale Investment Management Inc. bought a new stake in Concert Pharmaceuticals during the first quarter worth $143,000. American International Group Inc. raised its position in Concert Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 10,156 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 677 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in Concert Pharmaceuticals during the second quarter worth $181,000. Finally, Oxford Asset Management bought a new stake in Concert Pharmaceuticals during the first quarter worth $237,000. 62.37% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Virginia Retirement Systems ET AL Has $209,000 Holdings in Concert Pharmaceuticals, Inc. (CNCE)” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thestockobserver.com/2017/09/13/virginia-retirement-systems-et-al-has-209000-holdings-in-concert-pharmaceuticals-inc-cnce.html.
CNCE has been the topic of several analyst reports. HC Wainwright initiated coverage on shares of Concert Pharmaceuticals in a research report on Monday, July 24th. They set a “buy” rating and a $20.00 price target on the stock. Zacks Investment Research raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. ValuEngine raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Aegis reissued a “buy” rating and issued a $25.00 price objective on shares of Concert Pharmaceuticals in a research report on Monday, June 12th. Finally, BidaskClub lowered shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Concert Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $24.80.
Concert Pharmaceuticals, Inc. (NASDAQ CNCE) opened at 14.95 on Wednesday. The stock has a 50 day moving average of $14.70 and a 200 day moving average of $14.75. Concert Pharmaceuticals, Inc. has a 12 month low of $7.11 and a 12 month high of $19.11. The company’s market capitalization is $339.17 million.
Concert Pharmaceuticals (NASDAQ:CNCE) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.04. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.20 million. Concert Pharmaceuticals had a negative return on equity of 61.98% and a negative net margin of 60,681.70%. Equities analysts anticipate that Concert Pharmaceuticals, Inc. will post ($2.18) EPS for the current fiscal year.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.